This new combination therapy provides stronger kidney protection and cardiovascular risk reductionfurther advancing person-centered care
Given the substantial disease burden and adverse health outcomes associated with this comorbidity, interventions aimed at reducing this risk for depression in the Type 2 diabetes population are crucial, particularly among older adults who are disproportionately affected by both conditions. Guo noted that previous research suggested that GLP-1RAs a drug also used to treat obesity and kidney disease may alleviate depression symptoms due to its ability to cross the blood-brain barrier
Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M
Moreover, we anticipate further pharmacovigilance studies, cohort analyses, and clinical trials in the future to develop evidence-based treatment strategies for patients experiencing GLP-1 RA-induced AP
M.GivertzM
They have been implicated in promoting neuroprotection, improving neurological structure and functions, attenuating apoptosis, mitigating oxidative stress, and modulating neuroinflammation [11,12,13]